20744-08-5

Basic information

• Product Name: 1-(4-chlorobutoxy)-4-methoxybenzene
• Synonyms: 1-(4-chlorobutoxy)-4-methoxybenzene
• CAS NO: 20744-08-5
• Molecular Weight: 214.692
• Mol File: 20744-08-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-chlorobutoxy)-4-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorobutoxy)-4-methoxybenzene(20744-08-5)
• EPA Substance Registry System: 1-(4-chlorobutoxy)-4-methoxybenzene(20744-08-5)

Safety Data

• Hazardous Substances Data: 20744-08-5(Hazardous Substances Data)

Upstream product

• 6940-78-9 4-chlorobutyl bromide 
• 150-76-5 4-methoxy-phenol 
• 110-56-5 1,4-dichlorobutane 

Downstream Products

• 25836-91-3 N-<4-(4-Methoxy-phenoxy)-butyl>-anilin 
• 1417997-99-9 C₂₃H₂₈O₆ 

Relevant articles and documents

Iron-Catalyzed Reductive Cyclization by Hydromagnesiation: A Modular Strategy Towards N-Heterocycles

A reductive cyclization to prepare a variety of N-heterocycles, through the use of ortho-vinylanilides, is reported. The reaction is catalyzed by an inexpensive and bench-stable iron complex and generally occurs at ambient temperature. The transformation likely proceeds through hydromagnesiation of the vinyl group, and trapping of the in situ generated benzylic anion by an intramolecular electrophile to form the heterocycle. This iron-catalyzed strategy was shown to be broadly applicable and was utilized in the synthesis of substituted indoles, oxindoles and tetrahydrobenzoazepinoindolone derivatives. Mechanistic studies indicated that the reversibility of the hydride transfer step depends on the reactivity of the tethered electrophile. The synthetic utility of our approach was further demonstrated by the formal synthesis of a reported bioactive compound and a family of natural products.

SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.